Shanghai Bao Pharmaceuticals Co Ltd Class H
HHKEX:26597.79
HKD
+0.28
(+3.66%)
ISIN
CNE100007B92
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Zheng Wang
- Full Time Employees
- 354
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 28 Luoxin Road Shanghai SH China 201900
- IPO Date
- Dec 10, 2025
- Website
- baopharma.com
- Similar Companies
- Business
- Shanghai Bao Pharmaceuticals Co., Ltd. is a clinical-stage biotechnology company that leverages synthetic biology to develop and deliver recombinant biologic drugs in Mainland China and Greater China regions, with operations spanning China, Hong Kong, Macau, and Taiwan. The company focuses on the discovery, development, manufacturing, and commercialization of recombinant protein therapies and antibody-based drugs, supported by proprietary chassis cell engineering platforms that integrate drug design and bioprocessing capabilities. Shanghai Bao Pharmaceuticals is headquartered in Shanghai and was founded to advance biologics through in-house R&D, scalable production, and strategic collaborations. Main products and services - Recombinant biologic drugs: development and commercialization of recombinant proteins and antibody-based therapeutics across multiple therapeutic areas. - Chassis cell engineering platforms: proprietary technology enabling optimized design and production of biologics, accelerating preclinical and clinical development. - Drug substance production: mammalian cell expression systems and microbial expression platforms used to generate drug substances for clinical and potential commercial use. - Finished dosage forms: development and manufacture of injectable formulations, lyophilized powders, and ready-to-use pre-filled syringe presentations. - Licensing and collaboration income: monetization of technology platforms, pipelines, and development rights through partnerships and licensing arrangements. - Clinical development services: sponsor-led clinical programs and regulatory submissions for product candidates, including Phase I–III planning and execution in China and potential international extensions. Latest major company changes - Strategic partnerships and alliances: engages in collaborations to advance pipeline programs and leverage external development and manufacturing capabilities, expanding access to additional markets and accelerating clinical progress. - Regulatory and clinical milestones: advances in clinical development of key assets with regulatory filing activity in major markets, including submissions related to NDA/NDA-like processes and potential regulatory approvals for select indications. - Product portfolio expansion: ongoing expansion of the recombinant protein and antibody drug portfolio, with additions to planned or active candidates and potential new platform-enabled therapies. - Corporate actions and organizational shifts: structural reorganization and capacity-building measures to enhance GMP-compliant biopharmaceutical manufacturing capabilities and to align with expanded clinical development plans. - Geographic and market expansion: broadened footprint beyond core domestic operations into broader regional markets, aligning manufacturing and development capabilities with regional demand. Additional context - Industry and segments: biopharmaceuticals; recombinant proteins; antibody therapeutics; synthetic biology; contract development and manufacturing organization (CDMO) potential capabilities. - Target markets: primarily China-based healthcare market with potential regional expansion into other Greater China markets and select international collaborations. - Geographic operations: headquarters in Shanghai, China; active operations and development programs in Mainland China with potential geographic diversification through partnerships. - Subsidiaries/parental relationships: operates as an independent entity focusing on its in-house R&D and development programs; potential strategic alliances with larger pharmaceutical groups for co-development and commercialization. - Founding year: not publicly specified in the provided materials; the company positions itself as a modern, GMP-oriented biopharmaceutical developer in Shanghai, China. Notes - The description emphasizes core activities, pipeline development, and production capabilities, along with recent strategic collaborations and expansion actions that reflect the company’s latest changes in the 1–2 year window.